149 related articles for article (PubMed ID: 27087021)
1. Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells.
Coelho SC; Almeida GM; Santos-Silva F; Pereira MC; Coelho MA
Expert Opin Drug Deliv; 2016 Aug; 13(8):1075-81. PubMed ID: 27087021
[TBL] [Abstract][Full Text] [Related]
2. Functionalized gold nanoparticles improve afatinib delivery into cancer cells.
Coelho SC; Almeida GM; Pereira MC; Santos-Silva F; Coelho MA
Expert Opin Drug Deliv; 2016; 13(1):133-41. PubMed ID: 26371512
[TBL] [Abstract][Full Text] [Related]
3. Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Coelho SC; Rocha S; Juzenas P; Sampaio P; Almeida GM; Silva FS; Pereira MC; Coelho MA
Expert Opin Drug Deliv; 2013 Oct; 10(10):1345-52. PubMed ID: 23937147
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma.
Coelho SC; Reis DP; Pereira MC; Coelho MAN
Pharmaceutics; 2019 Oct; 11(11):. PubMed ID: 31652942
[TBL] [Abstract][Full Text] [Related]
5. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
7. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
[TBL] [Abstract][Full Text] [Related]
8. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
[TBL] [Abstract][Full Text] [Related]
10. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
[TBL] [Abstract][Full Text] [Related]
11. Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
Coelho SC; Rocha S; Pereira MC; Juzenas P; Coelho MA
J Biomed Nanotechnol; 2014 Apr; 10(4):717-23. PubMed ID: 24734524
[TBL] [Abstract][Full Text] [Related]
12. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
13. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
14. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
Ferrer I; Quintanal-Villalonga Á; Molina-Pinelo S; Garcia-Heredia JM; Perez M; Suárez R; Ponce-Aix S; Paz-Ares L; Carnero A
J Exp Clin Cancer Res; 2018 Aug; 37(1):195. PubMed ID: 30119639
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening.
Wang L; Yin H; Huang S; Huang S; Huang C; Zhang Z; Liu H
Hum Exp Toxicol; 2022; 41():9603271221124094. PubMed ID: 36401358
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.
Curley SA; Cherukuri P; Briggs K; Patra CR; Upton M; Dolson E; Mukherjee P
J Exp Ther Oncol; 2008; 7(4):313-26. PubMed ID: 19227011
[TBL] [Abstract][Full Text] [Related]
18. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
20. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
